Thursday, May 5, 2016

BRIEF-Aerie Pharma completes late-stage study enrollment for eye drug

* Aerie pharmaceuticals completes enrollment of mercury 1

phase 3 registration trial of roclatantm (netarsudil/latanoprost

ophthalmic solution) 0.02%/0.005%

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)